Nymox Pharm (NYMXF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2024, filed Jun 3, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NYMXF SEC filings page.
This page shows Nymox Pharm (NYMXF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest balance sheet shows a liability-heavy structure, with financing inflows nearly offsetting operating cash consumption.
In FY2024, financing dependence is visible: operating cash flow was-$2.6M while financing cash flow supplied$2.6M , so the cash deficit was almost exactly offset by financing inflows. With capital expenditures at$0 , free cash flow matched operating cash flow, indicating that cash use came from ongoing operations rather than a reinvestment cycle. This combination describes a company whose reported cash movement relied on financing to bridge current needs, not on cash generated by operations.
Balance-sheet solvency is the central constraint: liabilities of
Short-term liquidity is even tighter than the solvency measure alone conveys. A 0.1x current ratio and current assets of
Financial Health Signals
Nymox Pharm does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2024.
Cash & Balance Sheet
Nymox Pharm recorded an outflow of $717K in free cash flow in Q4 2024, representing a cash shortfall after capex. This represents an increase of 20.1% from the same quarter a year earlier.
Nymox Pharm held $74K in cash as of Q4 2024; long-term debt is not reported for that period.
Not reported for Q4 2024.
Margins & Returns
None of these metrics is reported for Q4 2024.
Capital Allocation
Not reported for Q4 2024.
Not reported for Q4 2024.
NYMXF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
NYMXF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $654K+4.3% | $624K-6.7% | $627K-61.4% | $669K-78.7% | $271K-93.9% | $575K-53.6% | $1.6M+12.6% | $3.1M-18.4% |
| Current Assets | $653K+4.5% | $623K-4.7% | $625K-57.1% | $654K-77.5% | $214K-94.9% | $461K-48.2% | $1.5M+40.5% | $2.9M-14.2% |
| Cash & Equivalents | $74K+5.7% | $41K-46.1% | $70K-95.0% | $76K-97.2% | $132K-96.8% | $351K-47.8% | $1.4M+69.0% | $2.7M-13.9% |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $34K0.0% |
| Total Liabilities | $7.4M+95.5% | $6.9M+169.2% | $3.8M+80.4% | $2.6M+8.6% | $3.1M+40.4% | $2.4M-9.7% | $2.1M+8.1% | $2.4M+4.4% |
| Current Liabilities | $7.4M+95.5% | $6.9M+169.2% | $3.8M+80.4% | $2.6M+9.1% | $3.1M+43.7% | $2.4M-5.8% | $2.1M+18.0% | $2.4M+29.3% |
| Non-Current Liabilities | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $11K-97.5% |
| Long-Term Debt | N/A | N/A | N/A | $11K-94.9% | $55K-76.3% | $114K+5.6% | $173K-24.1% | $216K |
| Total Equity | -$6.8M-113.5% | -$6.3M-231.0% | -$3.2M-558.3% | -$1.9M-346.1% | -$2.9M-228.9% | -$1.8M-29.4% | -$482K+4.7% | $773K-51.2% |
| Retained Earnings | -$212.5M-2.2% | N/A | -$208.0M-4.4% | N/A | N/A | N/A | -$199.1M-3.4% | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Goodwill.
NYMXF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$717K+20.1% | N/A | -$897K+28.2% | -$1.3M+3.3% | -$909K-158.4% | -$988K+76.5% | -$1.2M+44.5% | -$1.3M+56.5% |
| Capital Expenditures | $0 | N/A | $0 | $0 | $0 | $3K | $0-100.0% | $0 |
| Free Cash Flow | -$717K+20.1% | N/A | -$897K+28.2% | -$1.3M+3.3% | -$909K-158.4% | -$991K+76.4% | -$1.2M+44.6% | -$1.3M+56.5% |
| Investing Cash Flow | $0 | N/A | $0 | $0 | $0 | -$3K | $0+100.0% | $0 |
| Financing Cash Flow | $750K-15.8% | N/A | $891K+1813.5% | $1.2M+2111.7% | $690K-62.5% | -$61K-101.5% | -$52K+11.9% | -$60K-1.7% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
NYMXF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Assets | N/A | N/A | N/A | N/A | N/A | -241.2%+169.6pp | N/A | N/A |
| Current Ratio | 0.09-0.1x | 0.09-0.2x | 0.16-0.5x | 0.25-1.0x | 0.07-1.8x | 0.19-0.2x | 0.69+0.1x | 1.24-0.6x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.28-1.2x |
| Asset Turnover | N/A | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.000.0x | N/A | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, FCF Margin.
Note: Shareholder equity is negative (-$6.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Nymox Pharm NYMXF | FY2024 | N/A | N/A | N/A | $21K | — |
| Orgenesis Inc ORGS | FY2024 | $1.0M | N/A | N/A | $7.9M | — |
Where Nymox Pharm Ranks
Frequently Asked Questions
What is Nymox Pharm's free cash flow?
Nymox Pharm (NYMXF) recorded an outflow of $2.6M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nymox Pharm's operating cash flow?
Nymox Pharm (NYMXF) recorded an outflow of $2.6M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Nymox Pharm's total assets?
Nymox Pharm (NYMXF) had $654K in total assets as of fiscal year 2024, including both current and long-term assets.
What are Nymox Pharm's capital expenditures?
Nymox Pharm (NYMXF) reported no capital expenditure during fiscal year 2024.
What is Nymox Pharm's current ratio?
Nymox Pharm (NYMXF) had a current ratio of 0.09 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Nymox Pharm's P/E ratio?
Nymox Pharm (NYMXF) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $21K as of Sep 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Nymox Pharm's price-to-sales ratio?
Nymox Pharm (NYMXF) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $21K as of Sep 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Nymox Pharm's debt-to-equity ratio negative or not reported?
Nymox Pharm (NYMXF) has negative shareholder equity of -$6.8M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.